Table 3.
Hemagglutination inhibition and microneutralization antibody responses in Study Group 3 (15 μg A/H7N9 + AS03A) 21 days after the second vaccination, against the vaccine strain (A/Hong Kong/125/2017) and drifted H7N9 strains (A/Shanghai/2/2013 and A/Guangdong/17SF003/2016), by age-group.
| Age group (years) | |||||
|---|---|---|---|---|---|
| 19–34 | 35–49 | 50–64 | 19–64 | ≥ 65 | |
| N=53 | N=26 | N=20* | N=99* | N=67 | |
| H7N9 strain | Hemagglutination Inhibition Antibody Responses | ||||
| Titer ≥40 – % (95% CI) | |||||
| A/Hong Kong/125/2017 | 87 (72, 93) | 69 (48, 86) | 60 (36, 81) | 76 (66, 84) | 49 (37, 62) |
| A/Shanghai/2/2013 | 60 (46, 74) | 35 (17, 56) | 37 (16, 62) | 49 (39, 59) | 27 (17, 39) |
| A/Guangdong/17SF003/2016 | 55 (40, 68) | 46 (27, 67) | 25 (9, 49) | 46 (36, 57) | 25 (16, 37) |
| GMT (95% CI) | |||||
| A/Hong Kong/125/2017 | 76 (59, 98) | 49 (33, 73) | 40 (22, 74) | 59 (48, 73) | 28 (21, 38) |
| A/Shanghai/2/2013 | 43 (33, 55) | 22 (16, 32) | 24 (13, 44) | 32 (26, 39) | 18 (14, 23) |
| A/Guangdong/17SF003/2016 | 35 (27, 46) | 28 (19, 41) | 16 (9, 28) | 28 (23, 35) | 14 (11, 18) |
| Microneutralization Antibody Responses | |||||
| Titer ≥40 – % (95% CI) | |||||
| A/Hong Kong/125/2017 | 92 (82, 98) | 88 (70, 98) | 55 (32, 77) | 84 (75, 90) | 55 (43, 67) |
| A/Shanghai/2/2013 | 73 (59, 84) | 58 (37, 77) | 55 (32, 77) | 65 (55, 75) | 37 (26, 50) |
| A/Guangdong/17SF003/2016 | 43 (30, 58) | 27 (12, 48) | 10 (1, 32) | 32 (23, 42) | 16 (8, 27) |
| GMT (95% CI) | |||||
| A/Hong Kong/125/2017 | 86 (69, 109) | 62 (47, 82) | 48 (30, 79) | 70 (59, 84) | 39 (30, 49) |
| A/Shanghai/2/2013 | 54 (43, 69) | 34 (25, 47) | 35 (21, 56) | 44 (37, 53) | 28 (22, 35) |
| A/Guangdong/17SF003/2016 | 27 (22, 33) | 20 (14, 29) | 17 (11, 26) | 23 (19, 27) | 14 (11, 17) |
*
N=19 for 50–65 years and N=98 for 19–64 years for the samples tested against A/Shanghai/2/2013